{"id":"W4225630787","doi":"10.1093/neuonc/noac116","title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":501,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Montreal Neurological Institute and Hospital","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; National Institute of Neurological Disorders and Stroke; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Temozolomide; Medicine; Internal medicine; Nivolumab; Placebo; Regimen; Dacarbazine; Chemoradiotherapy; Gastroenterology; Radiation therapy; Progression-free survival; Randomized controlled trial; Clinical endpoint; Chemotherapy; Oncology; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001709797,0.001420541,0.00246885,0.0003623846,0.0004069904,0.001033664,0.001165049,0.001366362,0.006431273],"category_scores_gemma":[0.001251702,0.0006314947,0.001562108,0.0003894308,0.0009298132,0.0007254516,0.00034392,0.002776182,0.001326353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001103597,"about_ca_system_score_gemma":0.001618899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001876551,"about_ca_topic_score_gemma":0.004754771,"domain_scores_codex":[0.9995849,0.0002433455,0.00001808809,0.00007276198,0.0000247907,0.0000561911],"domain_scores_gemma":[0.9992573,0.0001542733,0.0001908796,0.00006056086,0.00004758429,0.0002895155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9728397,0.006186181,0.0005887951,0.000512704,0.0009544599,0.00002957413,0.00004530341,0.0003981565,0.003059795,0.0001189387,0.001570075,0.0136964],"study_design_scores_gemma":[0.951445,0.04546693,0.001142195,0.00002952919,0.0003954645,0.00002725368,0.00001557357,0.0003293029,0.0003769139,0.0001116916,0.0006518752,0.000008299484],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764055,0.006955995,0.001006821,0.001577858,0.001197799,0.006337884,0.002587594,0.0002745889,0.003655944],"genre_scores_gemma":[0.9803565,0.003622002,0.001720451,0.001943162,0.0003981107,0.005503411,0.002194097,0.00004224562,0.00422001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006431273,"threshold_uncertainty_score":0.02151477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02156685144926639,"score_gpt":0.3125214745721496,"score_spread":0.2909546231228832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}